MARKET

YMTX

YMTX

Yumanity Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

11.05
-0.99
-8.22%
After Hours: 11.29 +0.24 +2.17% 18:28 09/17 EDT
OPEN
12.14
PREV CLOSE
12.04
HIGH
12.40
LOW
10.81
VOLUME
602.56K
TURNOVER
--
52 WEEK HIGH
27.00
52 WEEK LOW
8.21
MARKET CAP
113.88M
P/E (TTM)
-0.6799
1D
5D
1M
3M
1Y
5Y
Yumanity Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Yumanity Therapeutics (Nasdaq: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced the grant to one new employee of a non-stat...
GlobeNewswire · 09/09 20:15
Yumanity Therapeutics to Present at the H.C. Wainwright 23rd Global Investment Conference
BOSTON, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced ...
GlobeNewswire · 09/09 12:00
BRIEF-Yumanity Appoints Michael Wyzga As CFO, Announces Inducement Grants
reuters.com · 08/16 11:19
Yumanity Therapeutics Q2 EPS $(1.03)
Yumanity Therapeutics (NASDAQ:YMTX) reported quarterly losses of $(1.03) per share.
Benzinga · 08/12 21:20
BRIEF-Yumanity Therapeutics Posts Q2 Loss Per Share Of $1.03
reuters.com · 08/12 21:06
-- Earnings Flash (YMTX) YUMANITY THERAPEUTICS Posts Q2 Revenue $2.11M
MT Newswires · 08/12 16:21
Yumanity Therapeutics to Present at the BTIG Virtual Biotechnology Conference
Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced that Company management will participate in...
GlobeNewswire · 08/06 11:00
The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 28)
Benzinga · 07/29 12:15
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of YMTX. Analyze the recent business situations of Yumanity Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average YMTX stock price target is 36.67 with a high estimate of 39.00 and a low estimate of 35.00.
EPS
Institutional Holdings
Institutions: 85
Institutional Holdings: 23.60M
% Owned: 229.02%
Shares Outstanding: 10.31M
TypeInstitutionsShares
Increased
8
425.02K
New
8
79.20K
Decreased
5
645.49K
Sold Out
5
63.29K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.49%
Pharmaceuticals & Medical Research
-0.10%
Key Executives
Non-Executive Chairman
N. Anthony Coles
President/Chief Executive Officer/Director
Richard Peters
Chief Financial Officer/Senior Vice President
Michael Wyzga
Executive Vice President
Ajay Verma
Other
Paulash Mohsen
Other
Brigitte Robertson
Lead Director/Independent Director
Richard Heyman
Independent Director
Patricia Allen
Independent Director
David Arkowitz
Independent Director
Kimberlee Drapkin
Independent Director
Jeffery Kelly
Independent Director
Cecil Pickett
Independent Director
Lynne Zydowsky
No Data
About YMTX
Yumanity Therapeutics Inc., formerly Proteostasis Therapeutics, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of disease-modifying therapies for neurodegenerative diseases. The Company's technology platform enables the rapid screening for novel disease targets and disease modifying drugs that can overcome toxicity in disease-causing gene networks. The Company's product candidate, YTX-7739, is in Phase I clinical trials for the treatment and disease modification of Parkinson's disease and YTX-9184, in IND-enabling studies for the treatment of dementia with Lewy bodies. The Company's pipeline consists of additional programs for the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's Disease) and frontotemporal lobar degeneration (FTLD) is undergoing research through Merck.

Webull offers kinds of Yumanity Therapeutics Inc stock information, including NASDAQ:YMTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, YMTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading YMTX stock methods without spending real money on the virtual paper trading platform.